{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:16:33Z","timestamp":1787836593142,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.dmpk.2015.08.004","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T17:34:17Z","timestamp":1440783257000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2630-039X","authenticated-orcid":false,"given":"Katsutoshi","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Wakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Caltabiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2015.08.004_bib1","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1096\/fj.02-1062fje","article-title":"Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors","volume":"17","author":"Warnecke","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.dmpk.2015.08.004_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2215\/CJN.03840907","article-title":"Novel erythropoiesis-stimulating agents: a new era in anemia management","volume":"3","author":"Macdougall","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.dmpk.2015.08.004_bib3","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1111\/j.1523-1755.2005.09909.x","article-title":"Role of hypoxia in the pathogenesis of renal disease","volume":"68","author":"Eckardt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.dmpk.2015.08.004_bib4","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1681\/ASN.2008070804","article-title":"HIF in kidney disease and development","volume":"20","author":"Gunaratnam","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.dmpk.2015.08.004_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1073\/pnas.0508423103","article-title":"A\u00a0family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis","volume":"103","author":"Percy","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.dmpk.2015.08.004_bib6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","article-title":"Regulation of erythropoietin production","volume":"589","author":"Jelkmann","year":"2011","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.dmpk.2015.08.004_bib7","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.dmpk.2015.08.004_bib8","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/sj.ki.5001970","article-title":"New approaches to the management of anemia of chronic kidney disease: beyond Epogen and Infed","volume":"70","author":"Rastogi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.dmpk.2015.08.004_bib9","first-page":"13","article-title":"Novel approaches in erythropoietin","volume":"2","author":"Nayak","year":"2010","journal-title":"J\u00a0Chem Pharm Res"},{"key":"10.1016\/j.dmpk.2015.08.004_bib10","first-page":"138A","article-title":"Four-week safety, efficacy and pharmacodynamic study of prolyl hydroxylase inhibitor GSK1278863 in anemic non-dialysis subjects not receiving recombinant human erythropoietin","volume":"24","author":"Holdstock","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.dmpk.2015.08.004_bib11","unstructured":"Meadowcroft AM, Holdstock L, Maier R, Jones D, Johnson B, Cobitz AR, et\u00a0al. Four-week safety, efficacy and pharmacodynamic study of hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor GSK1278863 in anemic hemodialysis subjects switching from recombinant human erythropoietin. High impact clinical trials poster at J Am Soc Nephrol; 2013 [SA-PO1092]."},{"key":"10.1016\/j.dmpk.2015.08.004_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.dmpk.2015.08.004_bib13","unstructured":"Declaration of Helsinki \u2013 ethical principles for medical research involving human subjects [homepage on the internet]. Available from: http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/ [accessed 20.01.15]."},{"key":"10.1016\/j.dmpk.2015.08.004_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cpdd.83","article-title":"Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863","volume":"3","author":"Johnson","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.dmpk.2015.08.004_bib15","first-page":"191","article-title":"Determination of cytochrome P450 metabolic activity using selective markers","volume":"vol. 8","author":"Jurica","year":"2012"},{"key":"10.1016\/j.dmpk.2015.08.004_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256440","article-title":"Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals","volume":"10","author":"Garcia-Martin","year":"2006","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.dmpk.2015.08.004_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-pathol-011110-130321","article-title":"The HIF pathway and erythrocytosis","volume":"6","author":"Lee","year":"2011","journal-title":"Annu Rev Pathol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436715000518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436715000518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:52:43Z","timestamp":1761162763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715000518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1347436715000518"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2015.08.004","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2015.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}